Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Vir Biotech Shuns FDA Submission Plans For GSK-Partnered COVID-19 Treatment
In its Q2 earnings release,Vir Biotechnology Inc(NASDAQ:VIR) and its partnerGSK plc(NYSE:GSK) said that they do not plan to file a marketing application for sotrovimab for COVID-19 at this time.
The company also said it does not intend to pursue the U.S.-based Phase 3 COMET-STAR prophylaxis trial, citing evolving COVID-19 landscape and FDA discussions.
Discussions with the FDA remain ongoing regarding the appropriate path forward...
Login or create a forever free account to read this news
Sign up/Log in